Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast majority of obstructive sleep apnea cases, with 70-90% of sufferers experiencing the condition due to excess weight. As patients lose weight through GLP-1 treatments, their need for breathing assistance devices may disappear entirely.

Source Fool.com

Resmed Inc. Aktie

Aufwärts geht es heute für die Resmed Inc. Aktie. Seit gestern notiert das Papier um 2,03 % höher.
Mit 18 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung steht die Community der Resmed Inc. Aktie positiv gegenüber.
Das Kursziel von 256 € für Resmed Inc. impliziert eine deutliche Steigerung um über 20% gegenüber 199.0 €.

Like: 0

RMD

Teilen